Related Experiment Video
Updated: Aug 9, 2026

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
Published on: June 15, 2018
Charcot-Marie-Tooth neuropathy: clinical phenotypes of four novel mutations in the MPZ and Cx 32 genes
V A Street1, G Meekins, H P Lipe
1Bloedel Hearing Center, University of Washington, Seattle, WA 98195, USA.
Abstract:
Charcot-Marie-Tooth Hereditary Neuropathy is a heterogeneous syndrome associated with mutations in several different genes including peripheral myelin protein 22, myelin P0, connexin 32, and early growth response 2. There is considerable variability in the phenotypic expression of this syndrome and the relationship of this variability to mutation genotypes requires extensive analysis. Here we describe the phenotypes and genotypes of four new mutations underlying the Charcot-Marie-Tooth syndrome and document segregation with disease. Four families with Charcot-Marie-Tooth were ascertained, examined, and evaluated electrophysiologically. Each family had peripheral blood DNA screened for mutations in myelin protein 22, myelin P0, and connexin 32. Two families were found with new mutations in the myelin P0 gene: S140T in the extracellular domain and K236del in the cytoplasmic domain. All families showed segregation of the mutations with the Charcot-Marie-Tooth phenotype as did a new family with the rare G163R mutation in the membrane domain. A 49-year-old man with the S140T mutation demonstrated conduction block on electrophysiological testing. A family with a novel S49P mutation in the connexin 32 gene had a neuropathy with very slow nerve conduction. These new mutations in the myelin P0 and connexin 32 genes help to clarify the pathophysiology of the clinical Charcot-Marie-Tooth syndrome. The S140T mutation in myelin P0 can be associated with conduction block and Charcot-Marie-Tooth should be part of the differential diagnosis of that phenomenon. Mutations in the cytoplasmic domain of myelin P0 can cause clinical neuropathy. The S49P mutation in the connexin 32 gene can produce aspects of a demyelinating type of X-linked hereditary neuropathy.
Insights
This study identifies four novel Charcot-Marie-Tooth mutations in myelin P0 and connexin 32 genes. These findings clarify the genetic basis and varied clinical presentations of this hereditary neuropathy.
Area of Science:
- Genetics
- Neurology
- Molecular Biology
Background:
- Charcot-Marie-Tooth Hereditary Neuropathy (CMT) is a diverse neurological disorder caused by mutations in multiple genes.
- Significant variability exists in CMT's clinical presentation, necessitating genotype-phenotype correlation studies.
Purpose of the Study:
- To identify and characterize novel mutations associated with Charcot-Marie-Tooth Hereditary Neuropathy.
- To investigate the genotype-phenotype relationships in four families with CMT.
Main Methods:
- Genetic screening of peripheral blood DNA for mutations in myelin protein 22, myelin P0, and connexin 32 genes.
- Clinical examination and electrophysiological evaluation of affected individuals and families.
- Segregation analysis to confirm the link between mutations and the CMT phenotype.
Main Results:
- Identified two new myelin P0 mutations (S140T, K236del) and one new myelin P0 mutation (G163R).
- Documented a novel connexin 32 mutation (S49P) associated with slow nerve conduction.
- Observed that the S140T myelin P0 mutation can lead to conduction block, and cytoplasmic myelin P0 mutations cause neuropathy.
- The S49P connexin 32 mutation is linked to a demyelinating X-linked neuropathy.
Conclusions:
- New mutations in myelin P0 and connexin 32 genes contribute to understanding CMT pathophysiology.
- The S140T myelin P0 mutation should be considered in the differential diagnosis of conduction block.
- Mutations in myelin P0's cytoplasmic domain and connexin 32 can cause distinct clinical manifestations of hereditary neuropathy.
Related Concept Videos
Pleiotropy
Single Nucleotide Polymorphisms-SNPs
Pharmacogenomics: Identification of New Drug Targets

